# A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients

> **NCT03867123** · PHASE1 · COMPLETED · sponsor: **Laminar Pharmaceuticals** · enrollment: 18 (actual)

## Conditions studied

- Glioblastoma (GBM)

## Interventions

- **DRUG:** LAM561
- **RADIATION:** RT
- **DRUG:** TMZ

## Key facts

- **NCT ID:** NCT03867123
- **Lead sponsor:** Laminar Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-04
- **Primary completion:** 2020-07-01
- **Final completion:** 2020-07-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03867123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03867123, "A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03867123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*